Benzimidazole derivatives: preparation and pharmaceutical applications
The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to benzimidazole containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with dysregulation of histone deacetylase (HDAC).
1. A method of treatment of a disorder selected from the group consisting of inflammatory disorders, immune system disorders, cardiovascular diseases, fibrotic diseases, vascular diseases, viral diseases, neurological diseases, parasitic diseases and proliferative disorders, the method comprising administering a therapeutically effective amount of a compound of formula:
wherein
R 1 is selected from the group consisting of: H, and unsubstituted or substituted C 1 -C 10 alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, C 4 -C 9 heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, each of which may be unsubstituted or substituted with one or more substituents independently selected from the group consisting of: halo, ═O, ═S, —CN, —NO 2 , alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkylamino, acylamino, aminoalkyl, phenoxy, benzyloxy, alkylsulfonyl, arylsulfonyl, aminosulfonyl, —COOH, —C(O)OR 5 , —SH, - and acyl;
R 2 is selected from the group consisting of: H, halo, and unsubstituted or substituted C 1 -C 10 alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, C 4 -C 9 heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, each of which may be unsubstituted or substituted with one or more substituents independently selected from the group consisting of: halo, ═O, ═S, —CN, —NO 2 , alkyl, alkenyl, alkynyl, haloalkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, phenoxy, benzyloxy, alkylamino, acylamino, aminoalkyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, —COOH, —C(O)OR 5 , —SH, and acyl;
R 3 is selected from the group consisting of H, C 1 -C 6 alkyl, and acyl;
X and Y are the same or different and are independently selected from the group consisting of: H, halo, —CN, —NO 2 , —CF 3 , C 1 -C 4 alkyl, —COR 5 , —SR 6 , —OR 6 , and —NR 7 R 8 ;
R 5 is C 1 -C 4 alkyl;
R 6 is C 1 -C 4 alkyl;
R 7 and R 8 are each independently selected from the group consisting of: H, C 1 -C 6 alkyl, C 4 -C 9 cycloalkyl, C 4 -C 9 heterocycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;
or a pharmaceutically acceptable salt thereof,
to a patient in need thereof.
2. The method according to claim 1 , wherein R 3 is H.
3. The method according to claim 1 , wherein X and Y are each H.
4. The method according to claim 1 , wherein R 1 is selected from the group consisting of: H, and unsubstituted or substituted hydroxyalkyl, C 1 -C 10 alkyl, heteroalkyl, arylalkyl, heteroarylalkyl, and heterocycloalkyl, each of which may be unsubstituted or substituted as defined in claim 1 .
5. The method according to claim 1 , wherein R 1 is selected from the group consisting of: methyl; (pyridin-3-yl)methyl; 2-hydroxy-ethyl; 2,3-di-hydroxy-propyl; and 3-hydroxy-propyl.
6. The method according to claim 1 , wherein R 2 is selected from the group consisting of H, and unsubstituted or substituted C 1 -C 10 alkyl, arylalkyl, aryl, heteroaryl, heteroalkyl, and cycloalkyl, each of which may be unsubstituted or substituted as defined in claim 1 .
7. The method according to claim 1 , wherein R 2 is selected from the group consisting of 2-phenyl-propyl, 2-phenyl-ethyl, 4-methoxy-phenyl, 4-benzyloxy-3-methoxy-phenyl, pyridin-2-yl, and pyridin-4-yl.
8. The method of claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
10. The method according to claim 1 , wherein R 1 is selected from the group consisting of: 2-(piperidin-1-yl)-ethyl; 2-(pyrrolidin-1-yl)-ethyl; 2-diethylamino-ethyl; and 3-dimethylamino-2,2-dimethyl-propyl.
11. The method according to claim 1 , wherein the disorder is a proliferative disorder.
12. The method according to claim 11 , wherein the proliferative disorder is cancer.
13. The method according to claim 12 , wherein the cancer is selected from the group consisting of colon cancer, ovarian cancer, prostate cancer, breast cancer, lung cancer, liver cancer, pancreatic cancer, renal cancer, sarcoma, neuroblastoma, gastric cancer, multiple myeloma, myeloproliferative neoplasms and hematologic cancers.